NCT06321094Completed
Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%
Vericiguat in Patients With Acute Coronary Syndrome and Reduced Ejection Fraction: The EVE-ACSrEF Study
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 149 (actual)
- First submitted
- 6 Mar 2024
- Start date
- 31 Jan 2024
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT06321094
What you commit to
- Study type: Observational
- Participants enrolled: 149
- From 31 Jan 2024 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 3.Has severe hepatic insufficiency or renal insufficiency.
Age
- 4.Has malignancy or other non-cardiac condition limiting life expectancy to \<1 years.
Other
- 1.SBP\<100mmHg.
- 2.Is pregnant or breastfeeding or plans to become pregnant or to breastfeed during the course of the trial.
Who the study is looking for
- 1.Provide written informed consent for the trial.
- 2.Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction \[NSTEMI\], or ST elevation myocardial infarction \[STEMI\]) or coronary revascularization (coronary artery bypass grafting \[CABG\] or percutaneous coronary intervention \[PCI\]).
- 3.ejection fraction \<45%.
- 4.Be male or female, aged greater than18 and less than 90 on the day of signing informed consent.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Nanjing Medical University Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
Related publications
- Vericiguat in patients with acute coronary syndrome and reduced ejection fraction: the EVE-ACSrEF study.BMC Cardiovasc Disord · 2026 · PMID 41723351
This page is information, not medical advice. Discuss any trial with your doctor.